1-[(2-氯苯基)苯基甲基]哌嗪 | 109036-15-9

• 物质功能分类: 分析化学 - 对照品
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-[(2-氯苯基)苯基甲基]哌嗪
• 中文别名: 盐酸左西替利嗪SM杂质
• 英文名称: 1-((2-chlorophenyl)(phenyl)methyl)piperazine
• 英文别名: 1-(2-chloro-benzhydryl)-piperazine；1-(2-Chlor-benzhydryl)-piperazin；(+)-1-[(2-chlorophenyl)phenylmethyl]piperazine；1-[(2-chorophenyl)phenylmethyl]piperazine；1-<2-Chlor-benzhydryl>-piperazin；N-<2-Chlor-benzhydryl>-piperazin；1-[(2-Chlorophenyl)(phenyl)methyl]piperazine；1-[(2-chlorophenyl)-phenylmethyl]piperazine
• CAS: 109036-15-9
• 化学式: C₁₇H₁₉ClN₂
• mdl: MFCD05186073
• 分子量: 286.804
• InChiKey: RLZPNIGECDMAJH-UHFFFAOYSA-N

物化性质

• 沸点：
  154 °C(Press: 0.01 Torr)
• 密度：
  1.158±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.294
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-[(2-氯苯基)苯基甲基]哌嗪 在 (S)-(-)-1-苯乙基异氰酸酯 作用下， 以 丙酮 为溶剂， 反应 2.0h， 以45%的产率得到(R)-1-((2-chlorophenyl)(phenyl)methyl)piperazine
  参考文献：
  名称：

  一种(R)-1-((2-氯苯基)-(苯基)-甲基)-哌嗪 的拆分方法

  摘要：

  本发明属于手性药物杂质制备技术领域，主要涉及手性药物盐酸左西替利嗪杂质(R)‑1‑((2‑氯苯基)‑(苯基)‑甲基)‑哌嗪的拆分方法。本发明将消旋1‑((2‑氯苯基)‑(苯基)‑甲基)‑哌嗪和拆分剂(S)‑(‑)‑alpha‑甲苄基异氰酸酯溶解于有机溶剂中，反应产生(R)‑1‑((2‑氯苯基)‑(苯基)‑甲基)‑哌嗪‑(S)‑(‑)‑alpha‑甲苄基异氰酸酯盐的沉淀，经过滤，丙酮洗涤，得到(R)‑1‑((2‑氯苯基)‑(苯基)‑甲基)‑哌嗪‑(S)‑(‑)‑alpha‑甲苄基异氰酸酯盐，加水溶解，用饱和碳酸钠溶液调pH＝8.0，加入乙酸乙酯萃取，干燥，过滤，浓缩得(R)‑1‑((2‑氯苯基)‑(苯基)‑甲基)‑哌嗪。本发明具有产物纯度高，反应时间短，反应温度低，收率高等优点，而且溶剂为丙酮、乙酸乙酯，易得，无毒性，易回收，环境污染小。

  公开号：

  CN105924409B
• 作为产物：
  描述：

  哌嗪 、 1-氯-2-(氯苯基甲基)苯 在 potassium carbonate 、 potassium iodide 作用下， 以 乙腈 为溶剂， 生成 1-[(2-氯苯基)苯基甲基]哌嗪
  参考文献：
  名称：

  Structure–activity relationships of diphenylpiperazine N-type calcium channel inhibitors

  摘要：

  A novel series of compounds derived from the previously reported N-type calcium channel blocker NP118809 (1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one) is described. Extensive SAR studies resulted in compounds with IC50 values in the range of 10-150 nM and selectivity over the L-type channels up to nearly 1200-fold. Orally administered compounds 5 and 21 exhibited both anti-allodynic and anti-hyperalgesic activity in the spinal nerve ligation model of neuropathic pain. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.008

文献信息

• NOVEL PROCESS FOR PREPARING HIGHLY PURE LEVOCETIRIZINE AND SALTS THEREOF
  申请人：Zelikovitch Lior

  公开号：US20110230496A1

  公开（公告）日：2011-09-22

  A process for preparing pure levocetirizine and salts thereof, e.g., the levocetirizine dihydrochloride, and a pharmaceutical composition comprising levocetirizine dihydrochloride produced by the process are disclosed.

  本发明公开了一种制备纯左西替利嗪及其盐，例如左西替利嗪二盐酸盐的方法，以及由该方法生产的含左西替利嗪二盐酸盐的药物组合物。
• PROCESS FOR PRODUCING PIPERAZINESULFONAMIDE DERIVATIVES AND SALTS THEREOF
  申请人：Azwell Inc.

  公开号：EP1020443A1

  公开（公告）日：2000-07-19

  A process for advantageously producing compounds of general formula (III), wherein R1 represents hydrogen, alkyl having 1 to 6 carbon atoms, alkoxyl having 1 to 4 carbon atoms, halogen, hydroxyl, trifluoromethyl, nitro or amino, R2 represents substituted or unsubstituted phenyl or pyridyl, R3 and R4 each represents hydrogen, alkyl having 1 to 6 carbon atoms, hydroxyalkyl having 1 to 4 carbon atoms, cycloalkyl having 3 to 8 carbon atoms, or substituted or unsubstituted phenyl; and Y represents alkylene having 1 to 12 carbon atoms, and salts thereof.

  一种有利地生产通式(III)化合物的工艺，其中 R1 代表氢、具有 1 至 6 个碳原子的烷基、具有 1 至 4 个碳原子的烷氧基、卤素、羟基、三氟甲基、硝基或氨基，R2 代表取代或未取代的苯基或吡啶基，R3 和 R4 各自代表氢、具有 1 至 6 个碳原子的烷基、具有 1 至 4 个碳原子的羟烷基、具有 3 至 8 个碳原子的环烷基或取代或未取代的苯基；Y 代表具有 1 至 12 个碳原子的亚烷基及其盐类。
• Morren et al., Industrie Chimique Belge, 1957, vol. 22, p. 409,416
  作者：Morren et al.

  DOI：——

  日期：——
• An assembly of structurally diverse small and simple 5-aminomethylene derivatives of 2,4-thiazolidinedione and studies of their biological activity
  作者：Sandeep Mohanty、Sandeep G. Reddy、B. RamaDevi、Arun Chandra Karmakar

  DOI：10.1007/s00044-015-1447-0

  日期：2015.12

  The synthesis of a novel series of substituted 5-(aminomethylene)thiazolidine-2,4-diones was achieved using a wide range of heterocyclic models derived from eight drug-like molecules. The primary aim of this study was to combine medicinally known, biologically active molecules bearing a 2A degrees amine functionality, such as terbinafine, fluoxetine, atomoxetine, cetirizine, risperidone, aripiprazole, ziprasidone, and clopidogrel, with a thiazolidinedione ring via an amino-methylene linker. By targeting this synergistic approach to compounds with skeletal, functional, and stereochemical diversity, we have developed a simple synthetic concept to enrich the thiazolidinedione collection with various biological activities. The biological activities of the newly synthesized 5-(aminomethylene)thiazolidine-2,4-dione derivatives were explored. All compounds were found to have antibacterial activity, with compounds bearing pyridine or piperazine moieties showing good to excellent antibacterial activity. Compounds with piperazine moieties were also found to show good antifungal activity, whereas none of the synthesized compounds showed high cytotoxic activity.
• TROPOLONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF FOR PREVENTING AND TREATING ISCHEMIC DISEASES
  申请人：THE UPJOHN COMPANY

  公开号：EP0546102A1

  公开（公告）日：1993-06-16